Frequently Asked Questions
The global Adrenocorticotropic Hormone Market was valued at USD 1.5 Billion in 2022.
The Adrenocorticotropic Hormone Market is expected to grow at a CAGR of 4.10% between 2023 and 2030, reaching USD 1.98 Billion in 2030.
The synthetic segment dominates the Adrenocorticotropic hormone market in 2022.
The Hospital segment governs the demand for Adrenocorticotropic Hormones in the world.
In 2022, the Nephrotic Syndrome category is predicted to develop at a 7.3% CAGR.
North America accounts for roughly 40% of the Adrenocorticotropic hormone market.
The top players include Novartis AG, Hikma Pharmaceuticals PLC, Merck & Co., Inc. and Mallinckrodt.
Increasing Interest in Personalized Medicine, and Hormone Replacement Therapy is becoming more popular are the major market drivers.
ACTH tests are expensive and unreimbursed, and adrenal gland disorders are underappreciated are the major market restraints.
Adrenal gland problems are becoming more common, and ACTH tests are becoming more popular in developing countries are the major opportunities in the Adrenocorticotropic Hormone industry.